natgillin/translations-raw huggingface dataset:
The pharmaceutical composition according to claim 12, wherein the composition comprises lactose and/or modified lactose and/or sucrose and/or glucose and/or mannitol and/or modified mannitol and/or sorbitol and/or fructose and/or cellulose and/or cellulose derivatives and/or starch and/or modified starch and/or dextrin and/or dextrose and/or dextrate and/or maltodextrine and/or calcium and its salts (phosphates, carbonates, chlorides) and/or magnesium and its derivatives (oxide, carbonate, stearate), and/or crospovidone and/or copovidones and/or cyclodextrines and/or alginic acid and its salts and/or saccharine and/or its salts, and/or sodium and its salts (chloride, citrate, fumarate, carbonate) and/or aspartame and/or lactic acid and its salts and/or succinic acid and/or ascorbic acid and/or tartaric acid and/or colloidal silicon dioxide and/or cyclamate and/or benzoic acid and/or benzoic acid salts and/or parabens and/or parabens salts as fillers. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što pripravak sadrži laktozu i/ili modificiranu laktozu i/ili saharozu i/ili glukozu i/ili manitol i/ili modificirani manitol i/ili sorbitol i/ili fruktozu i/ili celulozu i/ili celulozne derivate i/ili škrob i/ili modificirani škrob i/ili dekstrin i/ili dekstrozu i/ili dekstrat i/ili maltodekstrin i/ili kalcijeve soli i/ili magnezijeve soli i/ili umreženi povidon i/ili kopovidone i/ili ciklodekstrine i/ili alginsku kiselinu i njezine soli i/ili saharin i/ili njegove soli, i/ili natrijeve soli i/ili aspartam i/ili mliječnu kiselinu i njezine soli i/ili jantarnu kiselinu i/ili askorbinsku kiselinu i/ili vinsku kiselinu i/ili koloidni silicijev dioksid i/ili ciklamat i/ili benzojevu kiselinu i/ili soli benzojeve kiseline i/ili parabene i/ili soli parabena kao punila.
wherein: is a cleavable amino group protecting moiety; and 
P' je zaštitna grupa amino grupe koja se može odvojiti; i
The compound or salt of claim 1 or 9, wherein R6 is hydrogen, fluorine, methyl, or methoxy. 
Spoj ili sol u skladu s patentnim zahtjevom 1 ili 9, naznačen time što je R6 vodik, fluor, metil ili metoksi.
No. 5,202,029 discusses a process for the purification ofHMG-CoA reductase inhibitors using HPLC. 
5,202,029 opisuje postupak pročišćavanja inhibitora HMG-CoA reduktaze uporabom HPLC-a.
The method of E 25, wherein the monoclonal antibody or monoclonal antibody fragment is pegylated. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 25, naznačen time, da monoklonsko antitijelo ili fragment monoklonskog antitijela je pegiliran.
A compound of formula I, according to claim 2, wherein R1 is hydrogen; R4 and R5 are independently hydrogen or F; R6 is hydrogen or C1-C6 alkyl. 
Spoj formule I, u skladu s patentnim zahtjevom 2, naznačen time što je R1 vodik; R4 i R5 su neovisno vodik ili F; R6 je vodik ili C1-C6 alkil.
a VL which comprises in sequence hypervariable regions CDR1', CDR2' and CDR3', said CDR1' having the amino acid sequence SEQ ID NO:4, said CDR2' having the amino acid sequence SEQ ID NO:5, and said CDR3' having the amino acid sequence SEQ ID NO:6. 
VL koji obuhvaća u nizu hipervarijabilna područja CDR1’, CDR2’ i CDR3’, gdje navedeno područje CDR1’ ima aminokiselinsku sekvencu SEQ ID NO:4, navedeno područje CDR2’ ima aminokiselinsku sekvencu SEQ ID NO:5, i navedeno područje CDR3’ ima aminokiselinsku sekvencu SEQ ID NO:6, dok su hipervarijabilna područja određena prema Kabat-definiciji.
The method according to claim 1, wherein the oxidant is selected from at least one of hydrogen peroxide, carbamide peroxide and benzoyl peroxide. The method according to claim 1, wherein the composition further comprises at least one hydrophilic gelling agent. The method according to claim 6, wherein the hydrophilic gelling agent is selected from at least one of glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, a carbomer polymer, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, and gelatin. 
Kompozicija za primjenu prema patentnom zahtjevu 1, gdje peroksid je odabran iz grupe koja se sastoji od vodik peroksida pri 3.5% do 6% ukupne kompozicije, karbamid peroksida pri 10% do 16% ukupne kompozicije, i benzoil peroksida pri 2.5% do 5% ukupne kompozicije Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, koja dalje sadrži najmanje jedan hidrofilni agens za geliranje odabran od glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol (RTM) polimera, alginske kiseline, natrij alginata, kalij alginata, amonij alginata, kalcij alginata, agara, karagenana, karuba gume, pektina, i želatina.
represents a hydrogen atom, a methyl group or an ethyl group; 
predstavlja atom vodika, metilnu skupinu ili etilnu skupinu;
Said matrix may be selected from the group consisting of: laminin, fibronectin, vitronectin, proteoglycan, entactin, collagen, collagen I, collagen IV, heparan sulfate, Matrigel (a soluble preparation from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells), a human basement membrane extract, and any combination thereof. 
Postupak u skladu s patentnim zahtjevom 5 ili 6, naznačen time što se matriks bira iz skupine koju čine: laminin, fibronektin, vitronektin, proteoglikan, entaktin, kolagen, kolagen I, kolagen IV, heparan-sulfat, topljivi pripravak iz stanica mišjeg Engelbreth-Holm-Swarm (EHS) sarkoma, ekstrakt ljudske bazalne membrane, te bilo koja njihova kombinacija.
The method of manufacturing a conversion material according to claim 12, wherein the weight content of the second phase is equal to or more than what necessary to establish percolation channels. 
Postupak proizvodnje materijala za pretvorbu u skladu s patentnim zahtjevom 12, naznačen time što se sadržaj druge faze kreće od 0,01 do najviše 70%, težinski.
Combined organic extracts were dried over Na2SO4 and concentrated to give compound 7h (2.2 g, 96%). 
Pomiješane organske ekstrakte osuši se preko Na»SOy, te koncentrira kako bi se dobilo spoj 7h (2,2 g, 96 %).
or L is a group of the formula -NHC(O)(CH2)s- in which s is an integer from 1 to 6; preferably, 1 to 3; more preferably, 2 or 3; most preferably 2; and -SR is the polypeptide (E10C)hPYY3-36 or (D11C)hPYY3-36 in which S is the sulfur atom of the cysteine thiol group. 
Konjugat u skladu s patentnim zahtjevom 5, formule 4 HR P20090245 TI CH(OCH;CH2)yOCH2CH;CHNHC(O)CH,CH2N gdje n je cijeli broj u rasponu od otprilike 600 do 750, a -SR je polipeptid (DL LC)hPYY 29, gdje S je atom sumpora u cisteinskoj tiolnoj skupini.
A method of culturing heterologous protein-secreting mammalian cells in a cell culture supernatant wherein the cell culture supernatant is maintained at a temperature that is set at X±0.9°C, wherein X has a value of from 35.1 to 36.5, such as wherein the temperature is set at 36±0.9°C, 36±0.5°C, 36±0.2°C, 36 °C, 35.1±0.9°C, 35.1±0.5°C, 35.1±0.2°C, 35.1°C, 36.5±0.9°C, 36.5±0.5°C, 36.5±0.2°C or 36.5°C, with the proviso that the temperature is set at less than 37°C, wherein the culture is a continuous culture. 
Postupak uzgoja sisavačkih stanica koje izlučuju heterologni protein u supernatantu kulture stanica, naznačen time što se supernatant kulture stanica održava na temperaturi podešenoj na 36 ± 0,9 °C, gdje je kultura stanica kontinuirana kultura, koju se održava uz gustoću od 1,4 × 106 do 2,8 × 106 stanica/ml, te gdje je sisavačka stanica stanica CHO.
wherein the L1 signaling data includes information corresponding to a current radio frequency (RF) channel within the signal frame; 
Postupak u skladu sa zahtjevom 1, naznačen time, što informacije koje odgovaraju aktualnom radio frekventnom (RF) kanalu obuhvaćaju indeks radio frekventnog kanala.
In one embodiment the antibody of the invention is coupled to a therapeutic agent such as a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji sadrži antitijelo iz bilo kojeg od patentnih zahtjeva 1-9 koje je vezano za terapijski agens, poželjno toksin, radioizotop, lijek ili citotoksični agens.
The method of claim 41, wherein the concentration of erythropoietin protein contacted with the cyanate is from about 2 mg/ml to about 5 mg/ml. 
Postupak prema patentnom zahtjevu 41, naznačen time što je koncentracija proteina eritropoctina koja je dovedena u kontakt sa cijanatom od oko 2 mg/ml do oko 5 mg/ml.
Packaging unit according to claim 1, 2 or 3, wherein the bottom part is provided with friction resistance increasing elements. 
Jedinica za pakiranje prema zahtjevu 1, 2 ili 3, naznačena time da je donji dio predviđen s elementima koji povećavaju otpornost na trenje.
This substrate was loaded with an average of about 97 mg of a 1:1 mixture of glycerin and propylene glycol, about 3 mg of nicotine, and about 0.1 mg of a mixture of flavorants. 
Ovaj supstrat napuni se sa prosječno oko 97 mg 1:1 smjese glicerina 1 propilenglikola, oko 3 mg nikotina i oko 0.L mg smjese mirisnih sredstava.
ii) weight median particle size d 50 of 0.5 to 2.0 µm, iii) weight particle size d 25 of 0.1 to 1.0 µm, as measured according to the sedimentation method, and 
volumnu raspodjelu čestica d75 od 0.7 do 3.0 µm, ii) medijan volume raspodjele čestice d50 od 0.5 do 2.0 µm, iii) volumnu raspodjelu čestica d25 od 0.1 do 1.0 µm, kao što je izmjereno prema postupku sedimentacije, i
The compound of claim 2, wherein R14 is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što R'* ge bira iz skupine koju čine: eh,
The isolated antibody of claim 1 which is a monoclonal, chimeric, human or humanized antibody, or an antigen-binding fragment of an antibody. 
Antitijelo iz bilo kojeg od patentnih zahtjeva 1-3 koje je monoklonsko, himerno, humano ili humanizirano antitijelo, ili fragment antitijela.
a hydrocarbon converter for decomposing a hydrocarbon containing fluid into carbon and hydrogen, wherein the hydrocarbon converter comprises at least one process chamber having at least one inlet for a hydrocarbon containing fluid and at least one outlet for carbon and hydrogen, and wherein the hydrocarbon converter comprises at least one unit for introducing energy into the process chamber, the energy consisting at least partially of heat, wherein the at least one unit for introducing energy into the process chamber is designed in such a way that it can generate, at least locally, temperatures above 1000° C.; 
Uređaj za stvaranje sintetskog plina obuhvaća: pretvornik ugljikovodika za razgradnju tekućine koja sadrži ugljikovodik na ugljik i vodik, pri čemu pretvornik ugljikovodika sadrži najmanje jednu procesnu komoru koja ima najmanje jedan ulaz za tekućinu koja sadrži ugljikovodik i najmanje jedan izlaz za ugljik i/ili vodik i najmanje jednu jedinicu za uvođenje energije u procesnu komoru, energija se sastoji barem djelomično od topline;
The reaction mixture is subsequently treated with a metal hydroxide base in water, followed by HCl or another suitable acid, for example, H2SO4, followed by a solvent selected from isopropyl acetate and 2-methyltetrahydrofuran (Me-THF), thereby liberating the free acid form of the product of Formula Ic. After liberation of the free acid form of the compound of Formula Ic, the reaction mixture is treated with a tertiary amine to precipitate an ammonium salt form of the compound of Formula Ic. 
(1i) daljnji rad s reakcijskom smjesom dobivenom u koraku (i) tako da se ta reakcijska smjesa dalje obradi s LIOH u vodi nakon čega slijedi HCI u izopropil acetatu radi oslobađanja slobodne kiseline iz acetatnog oblika produkta; (ili) obrada slobodne kiseline proizvedene u koraku (ii) s tercijarnim aminom u izopropilacetatu da se istaloži sol 20 tercijarnog amina Formule Ic,
A dosage form comprising a therapeutically effective amount of trans-(±)-A9-tetrahydrocannabinol, wherein said dosage form is formulated with trans-(±)-A9-tetrahydrocannabinol in the crystalline form for use as a medicament. 
Oblik doziranja koji sadrži terapeutski učinkovitu količinu trans-(±)-A9-tetrahidrokanabinola, gdje je navedeni oblik doziranja formuliran s trans-(±)-A9-tetrahidrokanabinolom u kristalnom obliku za upotrebu kao lijek.
an outer sheath 6 configured to be removably attached to the syringe barrel 4, and comprising a projection 40 which is received by the channel 18 when the outer sheath 6 is attached to the barrel 4, thereby creating a seal, which prevents medicament from flowing therethrough, wherein the syringe barrel 4 and outer sheath 6 each comprise engagement means 44 which are configured to mutually engage with each other in order to create a second seal, which prevents leakage or discharge of the medicament from the chamber 14 when the outer sheath 6 is attached to the barrel 4, characterised in that the engagement means 44 is disposed on an external surface of the syringe barrel 4, at least adjacent or towards the end 12 of the barrel 4, which is opposite to that from which medicament is dispensed. 
futrole 6 dizajnirane da se može staviti i skinuti s cijevi šprice 4, koja uključuje ispupčenje 40 koje se spaja s kanalicom 18 kad se futrola 6 stavi na cijev 4 i tako stvara čep koji sprječava da lijek istječe iz kanalice, pri čemu cijev šprice 4 i futrola 6 tvore kopču 44 koja ima ulogu drugog čepa koji sprječava istjecanje lijeka iz komore 14 kad se futrola 6 stavi na cijev 4, naznačen time da se kopča 44 nalazi na vanjskoj površini cijevi šprice 4, blizu ili uz onaj kraj 12 cijevi 4, koji se nalazi nasuprot onome s kojeg se daje lijek.
The compound of Claim 4, selected from the group consisting of compounds having the formula (a) to (k), or a pharmaceutically acceptable salt thereof: 
Spoj prema patentnom zahtjevu 1, naznačen time što je izabran iz grupe koju čine spojevi koji imaju formulu (a) do (k), ili njegova farmaceutski prihvatljiva sol:
A method of treating a neoplastic disease or an immune disease comprising administering, either alone or in combination with other therapies, to a subject in need thereof an effective amount of the composition according to clause 15. 
Sastav prema zahtjevu 11, za upotrebu u postupku liječenja neoplastične bolesti ili imunološke bolesti koji sadrži administriranje efektivne doze spomenutog sastava, ili samog ili u kombinaciji sa drugim terapijama subjektu kojemu su potrebne.
In a further variation of each of the above embodiments and variations, R1 is substituted with one or more substituents selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, cyano, methylthio, methoxy, trifluoromethoxy, methyl, ethyl, trifluoromethyl, ethynyl, n-propanolyl and cyclopropyl. 
Spoj prema zahtjevu 8, naznačen time da R, je supstituiran sa jednim ili više supstituenata odabranih iz skupine koja sadrži vodik, fluoro, kloro, bromo, jodo, cijano, metiltio, metoksi, trifluorometoksi, metil, etil, trifluorometil, etinil, n-propanolil i ciklopropil.
reacting the amines 2 and 3, in mixture, with the pair of epoxides 4 and 5, in mixture, to obtain a mixture of four compounds (6, 7, 8 and 9); 
OČI: CO 00" b. reagiranja amina 2 13, u smjesi s parom spoksida 415, u smjesi, kako bi se dobila smjesa od četiri spoja (6, 7,
A compound of formula (I) 
Spoj formule (I) naznačen time da
The phosphate solid form for use of claim 14, wherein the pain is moderate to severe pain. 
Smjesa za upotrebu prema patentnom zahtjevu 15, naznačena time, što je bol umjerena do snažna bol.
detecting the actual leakage currents and generating a signal proportional thereto, 
(iii) detektiranjem stvarne parazitne struje i generiranjem proporcionalnog signala,
A process according to claim 17 or 18, wherein the layer of adhesive is applied to an upper surface of the peripheral flange by a roller, by spray coating, by a hot melt gun or by a printing technique. 
Postupak prema Zahtjevu 12 ili 13, gdje se na gornju površinu prirubnice izvedene duž oboda sloj ljepila nanosi pomoću valjka, raspršivanjem pomoću spreja, pomoću pištolja za topljenje ili nekom tehnikom tiska.
a heavy chain comprising a set of heavy chain CDR1, CDR2 and CDR3 as shown in SEQ ID NO: 36; and a light chain comprising a set of light chain CDR1, CDR2 and CDR3 as shown in SEQ ID NO: 35, 54 or 55, 
(1) teškog lanca antitijela, čija sekvenca odgovara sekvenci teškog lanca antitijela SEQ ID NO: 36, i (11) lakog lanca čija sekvenca odgovara sekvenci lakog lanca antitijela izabranoj iz grupe koju čine SEQ ID NO:
with a compound of the formula (IX) 
XVI a+b sa spojem s formulom (IX)
((2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate, or a pharmaceutically acceptable salt thereof, and ii) a non-selective beta-adrenergic receptor blocker selected from timolol, levobunolol or betaxolol, for use in reducing elevated intraocular pressure in an eye of a subject The combination for use as claimed in claim 1, wherein the non-selective beta-adrenergic receptor blocker is timolol. 
((2R,3$,4R,5R)-5-(6-(ciklopentilamino)-9H-purin-9-11)-3,4-dihidroksitetrahidrofuran-2-il)metil nitrat, ili njegovu farmaceutski prihvatljivu sol, i ii) neselektivni blokator beta-adrenergičkog receptora odabran između timolola, levobunolola ili betaksolola, za uporabu u snižavanju povišenog intraokularnog tlaka u oku subjekta. Kombinacija za uporabu u skladu s patentnim zahtjevom 1, pri čemu je neselektivni blokator beta-adrenergičkog receptora timolol.
the antibody is covalently attached to a capture label, a detection label, or a solid support, or 
(i) protutijelo je kovalentno priključeno na zahvatnu oznaku, detekcijsku oznaku ili na kruti nosač, ili
preparing a liquid pharmaceutical composition containing: the complex of macrocyclic chelate with a lanthanide, free macrocyclic chelate that is not under the form of an excipient X[X',L] in which L is the macrocyclic chelate and X and X' are a metal ion, in particular chosen independently from calcium, sodium, zinc and magnesium, and/or 
pripravu tekućeg farmaceutskog pripravka koji sadrži kompleks makrocikličkog kelata s lantanidom, te slobodni makrociklički kelat koji nije u obliku pomoćne tvari X[X',L] gdje L je makrociklički kelat i X i X' su metalni ion, naročito odabran neovisno od kalcija, natrija, cinka i magnezija, i slobodnog lantanida, pomoću miješanja otopine slobodnog makrocikličkog kelata i slobodnog lantanida, tako da se dobije kompleksiranje lantanida pomoću makrocikličkog kelata, te su količine slobodnog makrocikličkog kelata i slobodnog lantanida takve da sav lantanid ne kompleksira;
In some embodiments according to any of the methods described above in this section, the HCC is liver cell carcinoma, fibrolamellar variant of HCC, or mixed hepatocellular cholangiocarcinoma. In some embodiments according to any of the methods described above in this section, wherein the HCC is early stage HCC, non-metastatic HCC, primary HCC, advanced HCC, locally advanced HCC, metastatic HCC, HCC in remission, recurrent HCC, HCC in an adjuvant setting, or HCC in a neoadjuvant setting. 
Pripravak ili kombinacija za uporabu prema bilo kojem od zahtjeva 1-8, gdje je HCC karcinom stanica jetre, fibrolamelarna varijanta HCC-a, miješani hepatocelularni kolangiokarcinom, HCC ranog stadija, ne-metastatski HCC, primarni HCC, uznapredovali HCC, lokalno uznapredovali HCC, metastatski HCC, HCC u remisiji, ponavljajući HCC, HCC u adjuvansnom okruženju, ili HCC u ne-adjuvansnom okruženju.
The mucosal bioadhesive slow release carrier formulation according to claim 2, in which said acyclovir is present in an amount from 50 mg to 100 mg. 
Nosač bioadhezivan za sluznicu sa sporim oslobađanjem prema patentnom zahtjevu 11, naznačen time što je navedeni aciklovir prisutan u količini od 50 do 100 mg u navedenom nogaču.
to 50 wt.-%, particularly 2 to 20 wt.-%, more preferably 4 to 8 wt.-% like 4 to 9 wt.-% of a diuretic, preferably hydrochlorothiazide; 
diuretik od 1 do 50 masenih %, posebno od 2 do 20 masenih %, bolje od 4 do 8 masenih % i još bolje od 4 do 9 masenih %, poželjno hidroklorotiazid;
A combination consisting essentially of the B-lactamase inhibitor: or a pharmaceutically acceptable salt thereof, and sulbactam, or a pharmaceutically acceptable salt thereof, for use in the treatment of a bacterial infection. 
Kombinacija koja se u osnovi sastoji od inhibitora B-laktamaze: B Mom, = ili njegove farmaceutski prihvatljive soli i sulbaktama, ili njegove farmaceutski prihvatljive soli, radi liječenja bakterijske infekcije.
A method of treating or preventing a disease or disorder involving a cell expressing CLDN6 and being characterized by association of CLDN6 with its cell surface in a subject, comprising administering to said subject an antibody of any one of items 1-19, a conjugate of item 20 or 21 or a pharmaceutical composition of item 22. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1-6, konjugat prema patentnom zahtjevu 7 ili farmaceutska kompozicija prema patentnom zahtjevu 8 za upotrebu u postupku za liječenje ili prevenciju bolesti raka ili poremećaja koji obuhvaća stanicu koja eksprimira CLDNG6 i koja je naznačena vezom CLDNG6 s njezinom staničnom površinom kod subjekta.
The DRX spectra of the crystalline form present in the cream are indicated in Fig. 28 . A process for preparing cortexolone-17a-propionate in crystalline form I, wherein said crystalline form I is characterized by a DRX spectrum as represented in Figure 1 and by a DSC spectrum as represented in Figure 2 and by an IR spectrum as represented in Figure 3, said process comprising reacting a compound of Formula II: with a compound of Formula III R'OH (III) in the presence of a lipase from Candida, wherein R is CH3-CH2, and R' is a linear aliphatic chain containing 1-10 carbon atoms to give cortexolone-17a-propionate, and crystallizing said cortexolone-17a-propionate from tert-butylmethylether, to give cortexolone-17a-propionate in crystalline form I. 
Postupak priprave korteksolon-17a-propionata u kristalnom obliku I, naznačen time što navedeni kristalni oblik I ima karakteristični spektar DRX kao što je prikazan na Slici 1, spektar DSC kao što je prikazan na Slici 21 IR spektar kao što je prikazan na Slici 3, gdje se navedeni postupak sastoji u reakciji spoja Formule II: sa spojem Formule III R'OH (II) u prisutnosti lipaze iz kvasca Candida, gdje je R CH3-CH., a R' je nerazgranati alifatski lanac s 1-10 atoma ugljika, kako bi se dobilo korteksolon-17a-propionat, te u kristaliziranju navedenog korteksolon-174-propionata iz terc- butil-metil-etera kako bi se dobilo korteksolon-17a-propionat u kristalnom obliku I.
Item 10. The antitumor agent according to Item 9, wherein the antitumor agent is used for treating at least one cancer selected from the group consisting of head and neck cancers, esophageal cancers, gastric cancers, colonic cancers, rectal cancers, liver cancers, gallbladder and bile duct cancers, biliary tract cancers, pancreatic cancers, lung cancers, breast cancers, ovarian cancers, cervical cancers, endometrial cancers, renal cancers, bladder cancers, prostatic cancers, testicular tumors, bone and soft tissue sarcoma, leukemia, malignant lymphomas, multiple myelomas, skin cancers, brain tumors, and mesotheliomas. 
10.Protutumorsko sredstvo prema zahtjevu 9, naznačeno time, da se navedeno protutumorsko sredstvo upotrebljava za liječenje najmanje jednog raka odabranog iz skupine koja se sastoji od sljedećih vrsta raka: rak glave i vrata, rak jednjaka, rak želudca, rak debelog crijeva, rak rektuma, rak jetre, rak žučnog mjehura i žučnih vodova, rak bilijarnog trakta, rak gušterače, rak pluća, rak dojke, rak jajnika, rak cerviksa, endometrijski rak, rak bubrega, rak mjehura, rak prostate, tumor testisa, sarkom kostiju i mekog tkiva, leukemija, maligni limfomi, višestruki mijelomi, rak kože, tumori mozga i mezoteliomi.
or A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable carrier. 
Farmaceutski sastav sadrži tvar, ili njenu farmaceutski prihvatljivu sol, iz bilo kojeg od patentnih zahtjeva 1-17 1 farmaceutski prihvatljivi nosač.
A radiolabelled RUP25 compound of Formula (I) can be used in a screening assay to identify/evaluate compounds. 
Radiološki označen RUP25 spoj Formule (T) se može koristiti u ispitivanju promatranja da bi se identificirali/evaluirali spojevi.